Abstract
As mentioned above, TRIPS, which came into effect in 1995, basically requires all member countries to introduce product patents. Once the framework was announced, a number of researchers carried out their own studies on the impact of TRIPS on developing countries and released their research results.
This is a preview of subscription content, log in via an institution to check access.
References
“TRIPS, Patents and Access to Medicines: Proposals for Clarification and Reform” (briefing paper, Third World Network, June 2001).
S. La Croix and A. Kawaura, “Product Patent Reform and Its Impact on Korea’s Pharmaceutical Industry,” International Economic Journal 10, no. 1 (1996): 109–124.
Yun Sun Hee, “Korean Patent System for Innovation” (presentation, meeting of the National Innovation System, Competition and Cooperation – The Patent System in Next Generation – by the University of Tokyo and Kyoto University, Kyoto University, June 11, 2009): 5.
Hiroshi Akimoto, “R&D Strategy of the Japanese Pharmaceutical Industry and Bio Technology” (presentation material, Path of Bio Innovation and Future Development, Industry-Academy-Govt. Collaboration Workshop, Roppongi Hills, March 10, 2009): 5.
Padmashree Sampath, “Economic Aspects of Access to Medicines after 2005: Product Patent Protection and Emerging Firm Strategies in the Indian Pharmaceutical Industry,” United Nations University-Institute for New Technologies [UNU-INTECH] (Jan. 2005).
R. Joseph, “India’s Trade in Drugs and Pharmaceuticals: Emerging Trends, Opportunities and Challenges” (RIS discussion paper, no. 159, Nov. 2009): 1–45.
Alka Chadha, “Trips and Patenting Activity: Evidence from the Indian Pharmaceutical Industry” (working paper, no. 0512, National University of Singapore, Department of Economics, 2005.
Shubham Chaudhuri et al., “Estimating the Effects of Global Patent Protection in Pharmaceuticals: A Case Study of Quinolones in India” (NBER working paper, no. 10159, Dec. 2003, revised in 2006).
Cheri Grace, “The Effect of Changing Intellectual Property on Pharmaceutical Industry Prospects in India and China: Considerations for Access to Medicines,” DFID Health Systems Resource Centre (June 2004).
Jean Lanjouw, “The Introduction of Pharmaceutical Product Patents in India: ‘Heartless Exploitation of the Poor and Suffering’?” (NBER working paper, no. 6366, Jan. 1998).
Shamnad Basheer and T. Reddy, “The ‘Efficacy’ of Indian Patent Law: Ironing out the Creases in Section 3 (d),” scripted 5, no. 2 (August 2008).
Kalpana Chaturvedi and Joanna Chataway, “Strategic Integration of Knowledge in Indian Pharmaceutical Firms: Creating Competencies for Innovation,” International Journal of Business Innovation and Research 1, no. 1/2 (2006): 27–50.
Dinar Kale et al., “Reconfiguration of Competencies for Innovation – The Case of the Indian Pharmaceutical Industry” (presentation at a conference in honor of Keith Pavitt, Open University Business School, Nov. 13–15, 2003).
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2018 The Author(s)
About this chapter
Cite this chapter
Mitsumori, Y. (2018). Analysis of Preceding Studies. In: The Indian Pharmaceutical Industry. SpringerBriefs in Health Care Management and Economics. Springer, Singapore. https://doi.org/10.1007/978-981-10-6790-7_4
Download citation
DOI: https://doi.org/10.1007/978-981-10-6790-7_4
Published:
Publisher Name: Springer, Singapore
Print ISBN: 978-981-10-6789-1
Online ISBN: 978-981-10-6790-7
eBook Packages: Economics and FinanceEconomics and Finance (R0)